These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18486304)

  • 1. Re: Christian G. Stief, Hartmut Porst, Dieter Neuser, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236-44.
    Gacci M; Carini M; Maggi M
    Eur Urol; 2009 Jan; 55(1):e25-6. PubMed ID: 18486304
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
    Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Porst H; Sandner P; Ulbrich E
    Curr Urol Rep; 2008 Jul; 9(4):295-301. PubMed ID: 18765129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT; Roehrborn CG; Kaminetsky JC; Auerbach SM; Wachs B; Young JM; Esler A; Sides GD; Denes BS
    J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
    Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
    BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Hartmut Porst, Edward D. Kim, Adolfo R. Casabé, et al., for the LVHJ study team. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:1105-13.
    Serefoglu EC; Mitchell GC; Hellstrom WJ
    Eur Urol; 2012 May; 61(5):e45-6; author reply e47-8. PubMed ID: 22342774
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
    Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
    BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article].
    Caremel R; Oger-Roussel S; Behr-Roussel D; Grise P; Giuliano F
    Prog Urol; 2010 Oct; 20(9):616-26. PubMed ID: 20951929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Long-Term Treatment and Prognostic Factors of alpha1-Blockers for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Pilot Study Comparing Naftopidil and Tamsulosin Hydrochloride.
    Kaplan SA
    J Urol; 2011 Jan; 185(1):227. PubMed ID: 22082931
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Athanassios Oeconomou, Helmut Madersbacher, Gustav Kiss, Thomas J. Berger, Michael Melekos and Peter Rehder. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? a review of the literature. Eur Urol 2008;54:765-77.
    Brisinda G; Vanella S; Maria G
    Eur Urol; 2009 Jul; 56(1):e10-1; author reply e12-3. PubMed ID: 19375845
    [No Abstract]   [Full Text] [Related]  

  • 13. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study.
    Donatucci CF; Brock GB; Goldfischer ER; Pommerville PJ; Elion-Mboussa A; Kissel JD; Viktrup L
    BJU Int; 2011 Apr; 107(7):1110-6. PubMed ID: 21244606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
    Tamimi NA; Mincik I; Haughie S; Lamb J; Crossland A; Ellis P
    BJU Int; 2010 Sep; 106(5):674-80. PubMed ID: 20184577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Liu L; Zheng S; Han P; Wei Q
    Urology; 2011 Jan; 77(1):123-9. PubMed ID: 21195830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Zhao C; Kim SH; Lee SW; Jeon JH; Kang KK; Choi SB; Park JK
    BJU Int; 2011 Jun; 107(12):1943-7. PubMed ID: 21054754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L
    Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review.
    Laydner HK; Oliveira P; Oliveira CR; Makarawo TP; Andrade WS; Tannus M; Araújo JL
    BJU Int; 2011 Apr; 107(7):1104-9. PubMed ID: 20883484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Takao T; Tsujimura A; Kiuchi H; Matsuoka Y; Miyagawa Y; Nonomura N; Iwasa A; Kameoka H; Kuroda H; Matsumiya K; Uchida K; Yoshimura K; Okuyama A
    Int J Urol; 2008 Oct; 15(11):992-6. PubMed ID: 18775032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
    Roehrborn CG; Kaminetsky JC; Auerbach SM; Montelongo RM; Elion-Mboussa A; Viktrup L
    BJU Int; 2010 Feb; 105(4):502-7. PubMed ID: 19732051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.